MSB 10.4% $1.49 mesoblast limited

MSB Trading - 2020, page-1524

  1. 1,972 Posts.
    lightbulb Created with Sketch. 859
    Agree with you, lets hope MSB holds. Could not reply Col's post so borrowing tour instead

    Col
    I was talking about the final report to the FDA. The next line after your quote reads "The final module will be filed during January, and Mesoblast will request an expedited FDA review of the BLA under the product candidate’s existing Fast Track designation. If approved, remestemcel-L is planned to be launched in the US in 2020."That should be very clear what was filed and what was not.
  2. This thread is closed.

    You may not reply to this discussion at this time.

 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.